Skinny label biosimilars saved $1.5B from 2015 to 2020
A research letter in the Journal of the American Medical
Association found that skinny label biosimilars accounted for 62% of
biosimilars launched before 2022, representing an estimated $1.5 billion in
savings for Medicare between 2015 and 2020. Legal battles continue as
pharmaceutical companies try to protect their exclusivities, and the authors
note that "the path forward is for Congress to enact additional
legislation that reaffirms and strengthens the permissibility of skinny
labeling."
Full Story: Endpoints
News (free registration) (11/29)
No comments:
Post a Comment